Platelet count control in immune thrombocytopenic purpura patient: Optimum romiplostim dose profile
详细信息 查看全文
- 作者：Chia-Hung Tsaia ; James B. Busselb ; Allison A. Imahiyerobob ; Stanley I. Sandlera ; Babatunde A. Ogunnaikea ; ogunnaike@udel.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Immune thrombocytopenic purpura ; Biological system modeling ; Model-based control ; Nonlinear systems ; Optimization
- 刊名：Journal of Process Control
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：45
- 期：Complete
- 页码：76-83
- 全文大小：1960 K
文摘
- •
A pharmacokinetics/phamacodynamics (PKPD) model of romiplostim-mediated platelet production is customized for an immune thrombocytopenic purpura (ITP) patient.
- •
The model was used to determine optimum romiplostim dose profiles for stable platelet count control in the patient.
- •
Treatment frequency was identified as a major determining factor in the effectiveness of romiplostim treatment.
- •
A discrete PI controller is sufficient for maintaining stable platelet count in the patient.